EntryPoint Capital’s Ocular Therapeutix OCUL Stock Holding History

EntryPoint Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$137K	Sell	13,912 -25,082	-64%	-$227K	0.03%	728
2026 Q1	$330K	Buy	38,994 +26,989	+225%	+$257K	0.1%	431
2025 Q4	$146K	Hold	12,005	–	–	0.06%	593
2025 Q3	$140K	Sell	12,005 -12,257	-51%	-$147K	0.05%	596
2025 Q2	$225K	Sell	24,262 -17,769	-42%	-$139K	0.11%	421
2025 Q1	$308K	Buy	+42,031	New	+$323K	0.14%	307
2024 Q3	–	Sell	-20,597	Closed	-$141K	–	1129
2024 Q2	$141K	Buy	20,597 +5,285	+35%	+$32.6K	0.07%	607
2024 Q1	$139K	Buy	+15,312	New	+$109K	0.12%	257

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EntryPoint Capital's OCUL Position: Q2 2026 in Review

EntryPoint Capital reduced its Ocular Therapeutix (OCUL) stake by 64% in Q2 2026, selling an estimated $227K and leaving 13,912 shares worth $137K. The position accounts for 0.03% of the portfolio, ranked #728.

EntryPoint Capital first reported a position in OCUL in Q1 2024 and has held it in 8 quarters since. The position peaked at $330K in Q1 2026. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

EntryPoint Capital held 13,912 shares of Ocular Therapeutix worth $137K as of Q2 2026.
EntryPoint Capital sold 25,082 Ocular Therapeutix shares in Q2 2026, an estimated $227K.
Ocular Therapeutix made up 0.03% of EntryPoint Capital's portfolio in Q2 2026, its #728 holding.
EntryPoint Capital first reported a position in Ocular Therapeutix in Q1 2024 and has held it in 8 quarters since.
EntryPoint Capital's Ocular Therapeutix position peaked at $330K in Q1 2026.
263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.